Indiana vesiculovirus
| Amantadine | VSV | Viroporin inhibitor; blocks viral ion channel activity | Approved (other) | Japan | Viral ion channel (viroporin) | |
| Amiodarone | VSV | Non-competitive β-adrenergic inhibitor | Preclinical | — | Human (multiple) | |
| Amodiaquine | VSV | Methyltransferase inhibitor | Preclinical | — | Human HNMT | |
| Bortezomib | VSV | Proteasome inhibitor (26S subunit) | Preclinical | — | Human proteasome | |
| Brequinar | VSV | DHODH (DHODH) inhibitor | Preclinical | — | Human DHODH | |
| Clotrimazole | VSV | Block Viral Entry (KCa3.1 antagonist) | Preclinical | — | Human cytochrome P450 | |
| Cyclosporine | VSV | Calcineurin inhibitor; allows for inhibition of T cell activation | Preclinical | — | Human CYPs | |
| Doxycycline | VSV | — | Preclinical | — | Unknown | |
| Eflornithine | VSV | Enzyme-activated; irreversible inhibitor of ornithine decarboxylase | Preclinical | — | Human ODC | |
| Foscarnet | VSV | Pyrophosphate analog DNA polymerase inhibitor | Approved (other) | Japan | Viral RNA pol | |
| Indomethacin | VSV | Cyclo-oxygenase (COX) enzyme or prostaglandin G/H synthase inhibitor | Preclinical | — | Human COX | |
| JIB-04 | VSV | Human HDAC inhibitor | Preclinical | — | Human HDAC | |
| Monensin | VSV | — | Preclinical | — | Unknown | |
| Nelfinavir | VSV | HIV protease inhibitor | Approved (other) | Japan | Unknown | |
| Niclosamide | VSV | — | Preclinical | — | Human (multiple) | |
| Podofilox | VSV | — | Preclinical | — | Human topoisomerase | |
| Raloxifene | VSV | Selective estrogen receptor modulator | Preclinical | — | Human (multiple) | |
| Regorafenib | VSV | B-Raf; c-Kit; VEGFR2 inhibitor | Preclinical | — | Human PTK | |
| Saquinavir | VSV | Protease inhibitor | Approved (other) | JapanRussia | Unknown | |
| Sorafenib | VSV | B-Raf; FGFR-1; VEGFR-2 & -3; PDGFR-beta; KIT; and FLT3 inhibitor | Preclinical | — | Human PTK |